{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470476568
| type              = mab
| image             = 
| alt               = 
| mab_type          = mab
| source            = u
| target            = [[B-cell activating factor|BAFF]]
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 1143503-67-6
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| KEGG = D10083
| C=6518 | H=10008 | N=1724 | O=2032 | S=38
| molecular_weight = 146.25 kg/mol
}}

'''Tabalumab''' (LY 2127399) is an anti-[[B-cell activating factor]] (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and [[B cell]] malignancies.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf}}</ref><ref>http://www.lillyoncologypipeline.com/Pages/baff-antibody.aspx</ref> Tabalumab was developed by [[Eli Lilly and Company]].

A phase III clinical trial for [[rheumatoid arthritis]] was halted in Feb 2013.<ref>http://lilly.mediaroom.com/index.php?s=9042&item=136985</ref> In September 2014, a second phase III trial focussing on treating [[systemic lupus erythematosus]], was terminated early as the study failed to meet its primary endpoint.<ref>http://www.genengnews.com/gen-news-highlights/lilly-halts-tabalumab-development-for-lupus/81250423/</ref>

== References ==
<references/>

{{monoclonals for immune system}}
[[Category:Eli Lilly and Company]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}

Now dropped by Lilly due to lack of efficacy.